Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of CP-751,871 added to gemcitabine and cisplatin in advanced non-small cell lung cancer
2008-004008-30Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of figitumumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Overall survival. Started Jul 2009; status: completed.
02
Drugs
figitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-004008-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004008-30.